A Phase 2 interventional study of TNX-102 SL and Placebo in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-20.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 178th largest by enrollment of the 1,491 interventional ones that give a count, is one of 51 that started in 2014, is one of 168 in phase 2, and was the 586th registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Anthony Vesco · Sites in United States
Ages 8–18
Transcend Therapeutics · Sites in United States
Ages 18+
COMPASS Pathways · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,664 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 132 · Phase 2 234 · Phase 3 95 · Phase 4 90
First in 1991; this study’s year is marked. 51 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 245 is above the median of 69 across 2,201 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 65 across the 1,491 interventional studies, 107 across the 165 observational. Of the 1,135 that completed or were terminated, 491 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 1,664 have an industry lead sponsor. The 10 most frequent:
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Tonix Pharmaceuticals, Inc. has 7 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
154 of the studies in Stress Disorders, Post-Traumatic with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT04877093Phase 3Wake Forest University Health SciencesRepurposing Low-Dose Clonidine for PTSD in Veterans | 2027-03-31 |
| NCT06273527Phase 3University of California, San DiegoEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) | 2027-06-01 |
| NCT07217795University of Rhode IslandRecovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building | 2026-11 |
| NCT04585685Christal L BadourHealthy Recovery After Trauma Study | 2026-11 |
Add all 154 to your calendar (.ics) → With an account.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible subjects will return regularly to the study clinic for weekly or biweekly visits for assessments of efficacy and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 x placebo tablet ("placebo") to be taken sublingually once daily at bedtime.
Drug: Placebo
1 x TNX-102 SL 2.8mg tablet ("TNX-102 SL") and 1 x placebo tablet ("placebo") to be taken sublingually once daily at bedtime.
Drug: TNX-102 SL · Drug: Placebo
2 x TNX-102 SL 2.8mg tablets ("TNX-102 SL") to be taken sublingually once daily at bedtime.
Drug: TNX-102 SL
The Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12).
The mean change from baseline (Visit 2) in the Total CAPS-5 score after 12 weeks of treatment evaluated at Visit 9 (Week 12). The primary efficacy comparison will be the change from baseline in total CAPS-5 score for the 2.8 mg treatment arm compared to placebo. CAPS-5 score ranges from 0-80 with lower scores indicating less severe PTSD symptoms.
Time frame: Day 1, Week 12
Change From Baseline in Patients' Quality of Sleep Using the PROMIS Sleep Disturbance Scale After 12 Weeks of Treatment
Change from baseline in patients' quality of sleep using the PROMIS (Patient -Reported Outcome Measurement Information System) Sleep Disturbance scale after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Raw scores are converted to T-scores using published conversion tables. Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance
Time frame: Day 1, Week 12
Clinician Global Impression - Improvement Scale Responder Rate at Week 12
Responder rates in CGI-I (Clinician Global Impression - Improvement Scale) after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Responder rate is defined as the number of patients scored as either a 1 or 2 on CGI-I at Week 12. The score ranges from 1 to 7 with the following anchors for each score:1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse
Time frame: Week 12
Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score
Mean Change from Baseline in SDS Total Score at Week 12. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.
Time frame: Day 1, Week 12
| Milestone | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg |
|---|---|---|---|
| Started | 94 | 101 | 50 |
| Completed | 67 | 71 | 41 |
| Not completed | 27 | 30 | 9 |
The mean change from baseline (Visit 2) in the Total CAPS-5 score after 12 weeks of treatment evaluated at Visit 9 (Week 12). The primary efficacy comparison will be the change from baseline in total CAPS-5 score for the 2.8 mg treatment arm compared to placebo. CAPS-5 score ranges from 0-80 with lower scores indicating less severe PTSD symptoms.
| units on a scale | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg |
|---|---|---|---|
| The Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12). | -17.0 ± 1.98 | -19.2 ± 1.99 | -21.5 ± 2.41 |
Change from baseline in patients' quality of sleep using the PROMIS (Patient -Reported Outcome Measurement Information System) Sleep Disturbance scale after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Raw scores are converted to T-scores using published conversion tables. Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance
| units on a scale | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg |
|---|---|---|---|
| Change From Baseline in Patients' Quality of Sleep Using the PROMIS Sleep Disturbance Scale After 12 Weeks of Treatment | -7.9 ± 1.72 | -11.1 ± 1.74 | -11.0 ± 2.10 |
Responder rates in CGI-I (Clinician Global Impression - Improvement Scale) after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Responder rate is defined as the number of patients scored as either a 1 or 2 on CGI-I at Week 12. The score ranges from 1 to 7 with the following anchors for each score:1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse
| Participants | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg |
|---|---|---|---|
| Clinician Global Impression - Improvement Scale Responder Rate at Week 12 | 41 | 48 | 31 |
Mean Change from Baseline in SDS Total Score at Week 12. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.
| units on a scale | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg |
|---|---|---|---|
| Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score | -6.4 ± 1.11 | -7.9 ± 1.11 | -8.7 ± 1.35 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/94 (0%) | 3/94 (3.2%) | 36/94 (38.3%) |
| TNX-102 SL, 2.8 mg | 0/101 (0%) | 0/93 (0%) | 59/93 (63.4%) |
| TNX-102 SL, 5.6 mg | 0/50 (0%) | 1/50 (2%) | 35/50 (70%) |
| Event | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg |
|---|---|---|---|
| ProctitisGastrointestinal disorders | 0/94 | 0/93 | 1/50 |
| Perirectal abscessInfections and infestations | 0/94 | 0/93 | 1/50 |
| Anaphylactic reactionImmune system disorders | 1/94 | 0/93 | 0/50 |
| Multiple sclerosisNervous system disorders | 1/94 | 0/93 | 0/50 |
| Suicidal IdeationPsychiatric disorders | 1/94 | 0/93 | 0/50 |
| Event | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg |
|---|---|---|---|
| Hypoaesthesia OralGastrointestinal disorders | 2/94 | 36/93 | 18/50 |
| paraesthesia oralGastrointestinal disorders | 3/94 | 15/93 | 2/50 |
| Dry mouthGastrointestinal disorders | 10/94 | 4/93 | 8/50 |
| SomnolenceNervous system disorders | 6/94 | 11/93 | 8/50 |
| HeadacheNervous system disorders | 4/94 | 5/93 | 6/50 |
| SedationNervous system disorders | 1/94 | 2/93 | 6/50 |
| InsomniaPsychiatric disorders | 8/94 | 7/93 | 3/50 |
| GlossodyniaGastrointestinal disorders | 1/94 | 3/93 | 3/50 |
| Abnormal dreamsPsychiatric disorders | 5/94 | 1/93 | 1/50 |
| Upper respiratory tract infectionInfections and infestations | 5/94 | 3/93 | 2/50 |
| Age, Continuous(years) | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg | Total |
|---|---|---|---|---|
| Age | 31.9 ± 6.48 | 34.5 ± 8.11 | 34.7 ± 8.93 | 33.6 ± 7.79 |
| Sex: Female, Male(Participants) | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg | Total |
|---|---|---|---|---|
| Female | 6 | 9 | 4 | 19 |
| Male | 88 | 92 | 46 | 226 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 20 | 15 | 11 | 46 |
| Not Hispanic or Latino | 74 | 86 | 39 | 199 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | TNX-102 SL, 2.8 mg | TNX-102 SL, 5.6 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 0 | 4 |
| Asian | 3 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 21 | 27 | 12 | 60 |
| White | 61 | 68 | 33 | 162 |
| More than one race | 4 | 1 | 0 | 5 |
| Unknown or Not Reported | 4 | 1 | 4 | 9 |
Ran from Oct 2014 to primary completion in May 2016, 19 months.
Results were first posted in Jun 2024, 8 years 1 month after primary completion. A results delay was requested in Oct 2017.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 19 months is below that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine
Stress Disorders, Post-Traumatic →